Cargando…
Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses
Autores principales: | Srivastava, Minu, Murriel, Christopher, Yun, Rui, Mayes, Erin, Jie, Hyun-Bae, Axelrod, Fumiko, Xie, Ming-Hong, Bentley, Trevor, Cancilla, Belinda, Tam, Raymond, O'Young, Gilbert, Kapoun, Ann, Lewicki, John, Hoey, Tim, Gurney, Austin, Inkyung, Park Angie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649383/ http://dx.doi.org/10.1186/2051-1426-3-S2-P373 |
Ejemplares similares
-
RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations
por: Fischer, Marcus M., et al.
Publicado: (2017) -
Anti-DLL4, a cancer therapeutic with multiple mechanisms of action
por: Gurney, Austin, et al.
Publicado: (2011) -
WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death
por: Fischer, Marcus M., et al.
Publicado: (2017) -
Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo
por: Trindade, Alexandre, et al.
Publicado: (2017) -
SYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma
por: Liu, Xiao, et al.
Publicado: (2016)